ASH 2018 | Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma

Mark Bustoros

Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Phase II trial (NCT02916771) assessing the PFS and response rate following the combination of ixazomib, lenalidomide and dexamethasone for the treatment of high-risk smoldering multiple myeloma (SMM). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Busteros discusses the promising efficacy, tolerability and response rate of this combination, before revealing his future expectations for this treatment.

Share this video